HDAC6 and melanoma: HDAC6 is closely associated with resistance to sorafenib and gefitinib in lung cancer cells [47,48], resistance to microtubule-targeting anticancer drugs in melanoma cells [49], tamoxifen resistance in breast cancer cells [50], and bortezomib resistance in multiple myeloma cells [51].